2 o( P ?' f8 [0 L- w$ x8 A; l
临床上有依维莫司联合EGFR TKI作为易/特耐药之后的方案的研究: + s+ P* y2 x/ O' P v1 J" t1 w. G% }Everolimus and erlotinib as second- or third-line therapy in patients with advanced non-small-cell lung cancer. / t& ^% x" [0 x Qhttp://www.ncbi.nlm.nih.gov/pubmed/22968184- @5 j" V, X) t6 P